Clinical Trials Directory

Trials / Completed

CompletedNCT06432192

A Prospective, Monocentric Clinical Study for the Validation of in Vitro Diagnostic Tests Developed by Firalis

ApoDiag: A Prospective, Monocentric Clinical Study for the Validation of in Vitro Diagnostic Tests Developed by Firalis

Status
Completed
Phase
Study type
Observational
Enrollment
1,474 (actual)
Sponsor
Firalis SA · Industry
Sex
All
Age
18 Years – 85 Years
Healthy volunteers
Accepted

Summary

Firalis SA and its affiliate Amoneta Diagnostics SAS are developing novel in-vitro-diagnostic (IVD) tests for diverse diagnostic applications for major human diseases, including cardiovascular, and neurodegenerative disorders. These tests detect several gene mutations related to the above-mentioned pathologies. The development of IVD tools requires the evaluation of analytical parameters including biomarker stability. The present specific study therefore aims to collect whole blood samples in PAXgene DNA tubes to complete the analytical validation of IVD tools and the evaluation of the stability of the DNA in PAXgene DNA tubes and the reagents in the IVD tools.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTAPO-EasyTesting for the APOE genotype using the APO-Easy Genotyping test

Timeline

Start date
2024-01-02
Primary completion
2025-03-25
Completion
2025-03-25
First posted
2024-05-29
Last updated
2025-04-30

Locations

2 sites across 1 country: France

Source: ClinicalTrials.gov record NCT06432192. Inclusion in this directory is not an endorsement.

A Prospective, Monocentric Clinical Study for the Validation of in Vitro Diagnostic Tests Developed by Firalis (NCT06432192) · Clinical Trials Directory